Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIUZVI5ON)
  Drug Name Labetalol Drug Info Levobetaxolol (ophthalmic) Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antihypertensive Agents Cardiotonic Agents
  Structure

 Mechanism of Labetalol-Levobetaxolol (ophthalmic) Interaction (Severity Level: Moderate)
     Additive hypotensive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Labetalol Levobetaxolol (ophthalmic)
      Mechanism 1 Antihypertensive agent
Alpha-1 adrenergic receptor  Antagonist 		Antihypertensive agent
      Key Mechanism Factor 1
Factor Name Adrenergic receptor alpha-1 Structure Sequence
Protein Family G-protein coupled receptor 1 family
Protein Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Labetalol and Levobetaxolol (ophthalmic) 
      Mechanism 2 Antihypertensive agent
Alpha-1 adrenergic receptor  Antagonist 		Hypotensive effects
      Key Mechanism Factor 2
Factor Name Adrenergic receptor alpha-1 Structure Sequence
Protein Family G-protein coupled receptor 1 family
Protein Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
    Click to Show/Hide
      Mechanism Description
  • Additive hypotensive effects by the combination of Labetalol and Levobetaxolol (ophthalmic) 

Recommended Action
      Management Blood pressure and intraocular pressure monitoring is recommended during concurrent use. Patients should be advised to notify their physician if they experience a slow pulse, irregular heartbeat, dizziness, shortness of breath, or syncope.

References
1 Product Information. Timoptic (timolol ophthalmic). Merck &amp Co, Inc, West Point, PA.
2 Product Information. Acupress (carteolol ophthalmic). Otsuka American Pharmaceuticals Inc, Rockville, MD.